Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
RTI Health Solutions, Research Triangle Park, NC, USA.
Clin Endocrinol (Oxf). 2018 May;88(5):719-727. doi: 10.1111/cen.13574. Epub 2018 Mar 6.
Exogenous testosterone administration may affect blood clotting, polycythaemia, and may increase atherosclerosis, though any association with cardiovascular events is unclear. While the literature is inconclusive, some studies have suggested testosterone use may increase short-term risk of cardiovascular events and stroke, and injection testosterone may convey higher risks than other dosage forms.
We sought to evaluate the short-term cardiovascular risk of receiving injection testosterone.
We conducted a case-crossover analysis comparing injection testosterone exposure in the 7 days prior to an outcome event to referent windows in the past to estimate the acute association of cardiovascular outcomes with the receipt of testosterone injections.
We identified adult male testosterone users hospitalized with myocardial infarction (MI), stroke or a composite of MI, stroke or unstable angina in US commercial claims (2000-2013) or Medicare (2007-2010) databases.
We identified testosterone use for the patients from pharmacy dispensing claims or in-office procedure codes in the insurance billing data.
We identified 2898 commercially insured men with events and recent testosterone use, and 339 from Medicare. Injected testosterone was associated with an increased risk of adverse events (composite outcome of myocardial infarction, stroke or unstable angina) in the immediate postinjection period for the older, Medicare population only: commercial insurance, odds ratios (OR) = 0.98 (95% confidence intervals [CI]: 0.86-1.12); Medicare, OR = 1.45 (1.07, 1.98). This association was either greatly attenuated or not present when evaluating receipt of any testosterone dosage forms (injection, gel, patch, implant): commercial insurance, OR = 1.01 (0.92, 1.11); Medicare, OR = 1.26 (95% CI: 0.98-1.63).
Testosterone injections were uniquely associated with short-term risk of acute cardio- and cerebrovascular events in older adult men following injection receipt.
外源性睾丸酮的使用可能会影响血液凝结、红细胞增多,并可能增加动脉粥样硬化的风险,尽管其与心血管事件的关联尚不清楚。虽然文献尚无定论,但一些研究表明,睾丸酮的使用可能会增加短期心血管事件和中风的风险,且注射用睾丸酮的风险可能高于其他剂型。
我们旨在评估接受注射用睾丸酮的短期心血管风险。
我们进行了病例交叉分析,将发生结局事件前 7 天内接受注射用睾丸酮的暴露情况与过去的参照窗口进行比较,以评估心血管结局与接受睾丸酮注射之间的急性关联。
我们在美国商业索赔数据库(2000-2013 年)或医疗保险数据库(2007-2010 年)中确定了患有心肌梗死(MI)、中风或 MI、中风或不稳定型心绞痛的成年男性睾丸酮使用者。
我们从保险理赔数据中的药房配药记录或门诊手术代码中确定了患者的睾丸酮使用情况。
我们在商业保险数据库中确定了 2898 名患有事件且近期使用过睾丸酮的男性,在医疗保险数据库中确定了 339 名男性。在老年医疗保险人群中,注射用睾丸酮在注射后即刻与不良事件(心肌梗死、中风或不稳定型心绞痛的复合结局)风险增加相关:商业保险,比值比(OR)=0.98(95%置信区间[CI]:0.86-1.12);医疗保险,OR=1.45(1.07,1.98)。当评估任何睾丸酮剂型(注射、凝胶、贴片、植入物)的使用时,这种关联要么大大减弱,要么不存在:商业保险,OR=1.01(0.92,1.11);医疗保险,OR=1.26(95% CI:0.98-1.63)。
在接受注射后,睾丸酮注射与老年男性急性心脑血管事件的短期风险独特相关。